MedTrace Logo

Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

NCT00672282 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1218

Last updated 2009-05-27

No results posted yet for this study

Summary

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

Conditions

  • Non-Metastatic Prostate Cancer

Interventions

DRUG

Bicalutamide

150mg p.o. daily

DRUG

Placebo

Sponsors & Collaborators

  • Scandinavian Prostate Cancer Group

    collaborator NETWORK

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Peter Iversen, MD · Department of Urology Rigshospitalet Copenhagen Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-10-31
Completion
2008-08-31

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672282 on ClinicalTrials.gov